Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

Radotinib

Radotinib Structure
  • ₹0
  • Product name: Radotinib
  • CAS: 926037-48-1
  • MF: C27H21F3N8O
  • MW: 530.5
  • EINECS:
  • MDL Number:MFCD27956910
  • Synonyms:IY5511;Radotinib;Radotinib(IY-5511);4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phe...;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-;RADOTINIB; IY5511 HCL.;IY5511 HCl.
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Density :1.40±0.1 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form :solid
pka :12.94±0.70(Predicted)
color :Light yellow to yellow

Safety Information

Symbol(GHS): GHS hazard pictogramsGHS hazard pictogramsGHS hazard pictograms
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H302 Harmful if swallowed Acute toxicity,oral Category 4 Warning GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 Causes skin irritation Skin corrosion/irritation Category 2 Warning GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H317 May cause an allergic skin reaction Sensitisation, Skin Category 1 Warning GHS hazard pictograms P261, P272, P280, P302+P352,P333+P313, P321, P363, P501
H318 Causes serious eye damage Serious eye damage/eye irritation Category 1 Danger GHS hazard pictograms P280, P305+P351+P338, P310
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled Sensitisation, respiratory Category 1 Danger GHS hazard pictograms P261, P285, P304+P341, P342+P311,P501
H335 May cause respiratory irritation Specific target organ toxicity, single exposure;Respiratory tract irritation Category 3 Warning GHS hazard pictograms
H341 Suspected of causing genetic defects Germ cell mutagenicity Category 2 Warning P201,P202, P281, P308+P313, P405,P501
H361 Suspected of damaging fertility or the unborn child Reproductive toxicity Category 2 Warning P201, P202, P281, P308+P313, P405,P501
H370 Causes damage to organs Specific target organ toxicity, single exposure Category 1 Danger GHS hazard pictograms P260, P264, P270, P307+P311, P321,P405, P501
H413 May cause long lasting harmful effects to aquatic life Hazardous to the aquatic environment, long-term hazard Category 4
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P284 Wear respiratory protection.
P301+P312 IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P302+P352 IF ON SKIN: wash with plenty of soap and water.
P304+P341 IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P310 Immediately call a POISON CENTER or doctor/physician.
P321 Specific treatment (see … on this label).
P330 Rinse mouth.
P333+P313 IF SKIN irritation or rash occurs: Get medical advice/attention.
P342+P311 IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P363 Wash contaminated clothing before reuse.
P405 Store locked up.
P501 Dispose of contents/container to..…

Description

Radotinib, an inhibitor of Bcr–Abl tyrosine kinase,was approved in January 2012 in Korea as a second-line treatment for chronic myeloid leukemia (CML). Radotinib is a TKI with a similar structure to the second-generation TKI, nilotinib, in which a pyridyl group has been replaced with a pyrazinemoiety. The in vitro activity of radotinib against a variety of tumor cell lines is disclosed in an issued patent. Radotinib was significantly more potent than imatinib in all of the cell lines tested. The synthesis of radotinib via amide coupling is described in the patent literature.

Related product price